Proteomic Blood Test for Non-Small Cell Lung Cancer (NSCLC), VeriStrat
Lung cancer is a leading cause of death every year. Non-small cell lung cancer (NSCLC) is a subtype of lung cancer that involves the malignant transformation of the epithelial cells in the lungs. The disease has a poor prognosis with 30-50% of NSCLC patients dying within 5 years even after tumor resection. A large proportion of NSCLC tumors have mutations in the EGFR gene that is involved in cellular growth, proliferation, and tumor progression. The gene has a tyrosine kinase domain and interventions with tyrosine kinase inhibitors (TKIs) have been widely adopted in the management of NSCLCs that have common EGFR mutations (exon 19 deletions or exon 21 L858R mutation).
TKIs such as erlotinib, gefitinib, afatinib, osimertinib and dacomitinib have shown clinical efficacy in advanced NSCLC cases harboring common EGFR mutations. However, due to the toxicities associated with TKIs (dermatologic, gastrointestinal, pulmonary) it is desirable to identify advanced NSCLC patients who are likely to benefit from erlotinib and those who are unlikely to have a response in order to avoid the unnecessary toxicities.
Veristrat is test that performs proteomic analysis via the use of matrix-assisted laser desorption ionization mass spectrometry (MALDI TOF MS) of serum samples. The assay analyzes 8 proteins and provides either ‘good’ or ‘poor’ grade to identify patients likely to have progression-free survival (PFS) following erlotinib chemotherapy. While previously the NCCN included Veristrat testing prior to initiating TKI therapy, that recommendation was dropped in the 2021guideline due to advances in both next generation sequencing and treatments.
- Aids in identifying patients who are likely to benefit from erlotinib chemotherapy
No standard reference range is applicable. This is only a categorical test.
Serum, Serum separator tube (SST).
Stability
- Ambient: 1-3 days
- Refrigerated: 3-5 days
- Lung Cancer. 2017 Jul;109:101-108. [PMID: 28577938]
- BMC Cancer. 2018 Mar 20;18(1):310. [PMID: 29558888]
- J Natl Cancer Inst. 2007 Jun 6;99(11):838-46. [PMID: 17551144]
- Anticancer Res. 2016 Apr;36(4):1759-65. [PMID: 27069156]
- Lung Cancer. 2010 Sep;69(3):337-40. [PMID: 20036440]